Bell v. Sorin CRM USA
Opinion
FILED
United States Court of Appeals UNITED STATES COURT OF APPEALS Tenth Circuit
FOR THE TENTH CIRCUIT September 15, 2022
Christopher M. Wolpert
Clerk of Court
BRIANNA LEIGH BELL,
Plaintiff - Appellee/Cross-
Appellant,
Nos. 20-1392 & 20-1396
v. (D.C. No. 1:17-CV-01807-RM-STV)
(D. Colo.)
SORIN CRM USA, INC., d/b/a Livanova USA, Inc.,
Defendant - Appellant/
Cross-Appellee.
ORDER AND JUDGMENT*
Before McHUGH, MURPHY, and ROSSMAN, Circuit Judges.
Plaintiff Brianna Bell worked as an independent sales representative for Defendant Sorin CRM from May 2014 through April 2017. After Sorin declined to renew her contract, she sued Sorin on various theories of liability. A jury found in Bell’s favor on her claim of fraudulent inducement. The jury found that she sustained approximately $1.38 million in damages, and the district court entered judgment in her favor in this amount. In these cross-appeals, the parties primarily
*
This order and judgment is not binding precedent, except under the doctrines of law of the case, res judicata, and collateral estoppel. It may be cited, however, for its persuasive value consistent with Fed. R. App. P. 32.1 and 10th Cir. R. 32.1.
Appellate Case: 20-1392 Document: 010110739612 Date Filed: 09/15/2022 Page: 2
contest the award of damages. We conclude that Bell failed to prove damages with reasonable certainty, and therefore reverse and remand with instructions to issue judgment as a matter of law in Sorin’s favor.
I. BACKGROUND
As a Sorin sales representative, Bell sold different types of cardiac-rhythm management (“CRM”) devices, including pacemakers, defibrillators, and cardiac- resynchronization-therapy devices. CRM devices are prescribed by physicians for implantation in patients, but the trial evidence established that hospitals are the actual purchasers of these devices. Thus, hospital administrators are the individuals responsible for approving purchases of specific CRM devices.
Prior to working for Sorin, Bell worked as a sales representative for Medtronic, the largest CRM company in the United States. She believed that many physicians from her business network would be willing to shift to Sorin devices with her, but she was aware she might be unable to complete these sales unless Sorin had a contractual relationship with the fourteen hospitals at which her network of physicians performed implantations. Accordingly, she asked Sorin’s directors if Sorin had contractual access to these hospitals. She only signed her independent sales representative contract after she was reassured there would be no issues with this access or with her anticipated volume of sales. Once she began working as a Sorin sales representative, however, she discovered that Sorin was not on contract with any of the fourteen hospitals in question, and many of the Sorin implants requested by her network of physicians were denied by hospital administrators.
Appellate Case: 20-1392 Document: 010110739612 Date Filed: 09/15/2022 Page: 3
During her three-year period as an independent Sorin sales representative, Bell sold a total of 135 devices and received a total of $418,667.73 in commissions, plus $88,300 in bonuses. Her commissions were calculated based on a contractual formula that took into account the year in which the sale occurred, the type of device sold, and the sale price. The devices sold by Bell ranged in price from less than $3,000 to more than $26,000, depending on the specific device at issue and on the pricing schedule Sorin had established for that particular purchasing hospital. Correspondingly, Bell’s commissions for her 135 device sales also varied greatly, with her lowest-value sale earning her only $52.50, while her highest-value sale resulted in a $9,063.50 commission.
At trial, Bell presented testimony from three witnesses: herself, the Sorin area director with whom most of her pre-contract discussions occurred, and one of the physicians in her business network. This physician, Dr. John McKenzie, testified that Bell provided valuable technical support for the products she sold, so he intended to implant more Sorin devices after she became a Sorin sales representative. As a “rough estimate[],” he intended to move about 40% of his business, meaning “around 200 devices” annually, to Sorin. Appellant’s App. at 1110. Because hospital administrators contested virtually every request to purchase a Sorin device, however, he implanted significantly fewer Sorin devices than anticipated. McKenzie did not further elaborate on the numbers or types of devices he intended to implant, nor did he provide any explanation as to why certain intended implantations were approved while others were denied.
Appellate Case: 20-1392 Document: 010110739612 Date Filed: 09/15/2022 Page: 4
In his closing argument to the jury, Bell’s counsel suggested that the jury should calculate damages by dividing Bell’s total commissions by the number of devices she sold to determine the “average commission per device,” then multiplying this “average commission” by the number of devices Bell would have sold absent Sorin’s fraudulent representations regarding its contractual access to the hospitals in Bell’s sales territory. Appellant’s App. at 855-56. The jury ultimately found Sorin liable for fraudulent inducement and awarded Bell $1,380,745.47 in damages. Sorin filed a motion for judgment as a matter of law, arguing both that Bell had failed to present sufficient evidence of fraud and that she had not established damages to a reasonable degree of certainty. The district court denied this motion, and Sorin appealed.
On appeal, Sorin again challenges both the evidence in support of the fraud claim and the evidence of damages. Bell filed a cross-appeal, in which she argues she should have been awarded additional damages for her lost opportunity to work as a Sorin sales representative for a fourth year. She concedes her cross-appeal will be moot if we agree with Sorin that she failed to present sufficient evidence of damages to sustain the jury’s verdict.
Appellate Case: 20-1392 Document: 010110739612 Date Filed: 09/15/2022 Page: 5
II. ANALYSIS
We review de novo the district court’s denial of Sorin’s motion for judgment as a matter of law, drawing all reasonable inferences in favor of Bell. See Escue v. N. Okla. Coll., 450 F.3d 1146, 1156 (10th Cir. 2006). The parties agree that Delaware law governs the substantive issues in this diversity case, and they both assume that Sorin’s damages argument raises a substantive issue governed by Delaware law. Accordingly, we will likewise evaluate this argument under Delaware law.
Like other jurisdictions, Delaware “does not permit a recovery of damages which is merely speculative or conjectural.” Henne v. Balick, 146 A.2d 394, 396 (Del. 1958). “There must be some reasonable basis upon which a jury may estimate with a fair degree of certainty the probable loss which plaintiff will sustain in order to enable it to make an intelligent determination of the extent of this loss.” Id. Based on the need to prove damages with a fair degree of certainty, Delaware, like other jurisdictions, generally requires expert testimony to prove economic and financial damages. See, e.g., PJ King Enters. v. Ruello, 2008 WL 4120040, at *3 (Del. Super. Ct. July 1, 2008) (“Delaware law consistently holds that economic and financial damages require expert testimony.”); Villare v. Beebe Med. Ctr., Inc., 2014 WL 1095331, at *4 (Del. Super. Ct. Mar. 19, 2014) (granting summary judgment where plaintiff presented no expert testimony and “the proper measure of damages is lost profits,” on which “expert testimony is necessary”), aff’d, 108 A.3d 1226 (Del. 2015); cf. Conway v. Hercules Inc., 831 F. Supp. 354, 358 n.6 (D. Del. 1993) (stating that an expert may not be necessary in certain specific cases, such as when an
Free access — add to your briefcase to read the full text and ask questions with AI
Bell v. Sorin CRM USA (Bell v. Sorin CRM USA) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.